Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed~* 4 of the 11 modified American College of Rheumatology (ACR) Revised Criteria for the Classification of Systemic Lupus Erythematosus .~* SLEDAI \< 8 at Screening and at Baseline~* Stable immunosuppressive dose prior to randomization.~* Body Mass Index \< 30~* Able to swallow pills at randomization~Exclusion Criteria:~* Refuse of the patient or the legal responsible~* Use of vitamin D2 or D3 supplementation~* Significant renal insufficiency~* Primary hyperparathyroidism (known)~* History of nephrolithiasis (known)~* Diabetes mellitus requiring insulin therapy~* History of vertebral compression fractures (known)~* Pregnancy~* Use of bisphosphonates

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol 50.000IU/week (Type: ACTIVE_COMPARATOR): patients will receive vitamin D3 (50.000 IU/week) for 24weeks
- Placebo (Type: PLACEBO_COMPARATOR): patients receive placebo in similar capsules of cholecalciferol for 24weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).